Catalyst Pharmaceuticals Stock Analysis
CPRX Stock | USD 25.15 0.57 2.22% |
Catalyst Pharmaceuticals is undervalued with Real Value of 30.56 and Target Price of 33.0. The main objective of Catalyst Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Catalyst Pharmaceuticals is worth, separate from its market price. There are two main types of Catalyst Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Catalyst Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Catalyst Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Catalyst Stock trading window is adjusted to America/New York timezone.
Catalyst |
Catalyst Stock Analysis Notes
About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 6.02. The company had not issued any dividends in recent years. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. For more info on Catalyst Pharmaceuticals please contact Richard MBA at 305 420 3200 or go to https://catalystpharma.com.Catalyst Pharmaceuticals Investment Alerts
Catalyst Pharmaceuticals had very high historical volatility over the last 90 days | |
Over 83.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: With 81 percent ownership in Catalyst Pharmaceuticals, Inc. , institutional investors have a lot riding on the business |
Catalyst Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Catalyst Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
20th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
20th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Catalyst Largest EPS Surprises
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 |
Catalyst Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Catalyst Pharmaceuticals' ESG score is a quantitative measure that evaluates Catalyst Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Catalyst Pharmaceuticals' operations that may have significant financial implications and affect Catalyst Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Catalyst Pharmaceuticals Thematic Classifications
In addition to having Catalyst Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Health ManagementHealthcare providers, hospitals | |
![]() | BiotechBiotechnology and pharmaceuticals production and services |
Catalyst Stock Institutional Investors
Shares | Royce & Associates, Lp | 2024-12-31 | 1.9 M | Bank Of America Corp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Boston Partners Global Investors, Inc | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.2 M | Kennedy Capital Management Inc | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 913 K | Blackrock Inc | 2024-12-31 | 19.4 M | Vanguard Group Inc | 2024-12-31 | 8.4 M |
Catalyst Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.13 B.Catalyst Profitablity
The company has Profit Margin (PM) of 0.33 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.44 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.44.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.24 | 0.25 | |
Return On Capital Employed | 0.27 | 0.28 | |
Return On Assets | 0.19 | 0.20 | |
Return On Equity | 0.23 | 0.24 |
Management Efficiency
Catalyst Pharmaceuticals has return on total asset (ROA) of 0.1846 % which means that it generated a profit of $0.1846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2938 %, meaning that it created $0.2938 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.25 in 2025. Return On Capital Employed is likely to rise to 0.28 in 2025. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 654.8 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 6.14 | 6.45 | |
Tangible Book Value Per Share | 4.82 | 5.06 | |
Enterprise Value Over EBITDA | 10.03 | 10.53 | |
Price Book Value Ratio | 3.40 | 3.23 | |
Enterprise Value Multiple | 10.03 | 10.53 | |
Price Fair Value | 3.40 | 3.23 | |
Enterprise Value | 2 B | 2.1 B |
The strategic initiatives led by Catalyst Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 26th of March, Catalyst Pharmaceuticals shows the Mean Deviation of 2.14, risk adjusted performance of 0.0813, and Downside Deviation of 2.3. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Catalyst Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Catalyst Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Catalyst Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Catalyst Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Catalyst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Catalyst Pharmaceuticals Outstanding Bonds
Catalyst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Catalyst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Catalyst bonds can be classified according to their maturity, which is the date when Catalyst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Catalyst Pharmaceuticals Predictive Daily Indicators
Catalyst Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Catalyst Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 53494.76 | |||
Daily Balance Of Power | (0.61) | |||
Rate Of Daily Change | 0.98 | |||
Day Median Price | 25.49 | |||
Day Typical Price | 25.38 | |||
Price Action Indicator | (0.63) | |||
Period Momentum Indicator | (0.57) | |||
Relative Strength Index | 43.92 |
Catalyst Pharmaceuticals Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
28th of February 2025 Other Reports | ViewVerify | |
10K | 26th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13th of February 2025 Other Reports | ViewVerify | |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 21st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Catalyst Pharmaceuticals Forecast Models
Catalyst Pharmaceuticals' time-series forecasting models are one of many Catalyst Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Catalyst Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Catalyst Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Catalyst Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Catalyst shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Catalyst Pharmaceuticals. By using and applying Catalyst Stock analysis, traders can create a robust methodology for identifying Catalyst entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.44 | 0.46 | |
Operating Profit Margin | 0.40 | 0.42 | |
Net Profit Margin | 0.33 | 0.35 | |
Gross Profit Margin | 0.86 | 0.90 |
Current Catalyst Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Catalyst analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Catalyst analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
33.0 | Strong Buy | 8 | Odds |
Most Catalyst analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Catalyst stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Catalyst Pharmaceuticals, talking to its executives and customers, or listening to Catalyst conference calls.
Catalyst Stock Analysis Indicators
Catalyst Pharmaceuticals stock analysis indicators help investors evaluate how Catalyst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Catalyst Pharmaceuticals shares will generate the highest return on investment. By understating and applying Catalyst Pharmaceuticals stock analysis, traders can identify Catalyst Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 298.4 M | |
Common Stock Shares Outstanding | 124.9 M | |
Total Stockholder Equity | 727.6 M | |
Tax Provision | 52.4 M | |
Quarterly Earnings Growth Y O Y | 0.414 | |
Property Plant And Equipment Net | 3.6 M | |
Cash And Short Term Investments | 517.6 M | |
Cash | 517.6 M | |
Accounts Payable | 16.6 M | |
Net Debt | -514.8 M | |
50 Day M A | 22.499 | |
Total Current Liabilities | 120.7 M | |
Other Operating Expenses | 296.6 M | |
Non Current Assets Total | 227.8 M | |
Forward Price Earnings | 14.7059 | |
Stock Based Compensation | 22.3 M |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.